Maud Brandely

Last updated on 2016-07-22T11:05+0300.

About this image

sign

Quotes... Extracted quotes from

Maud Brandely said : “This is the first clinical study demonstrating that Transgene’s Vaccinia Virus from the Invir.IO platform is able to reach the tumor when administered intravenously. Importantly, through the production of 5-FU at therapeutic doses, we have also demonstrated the functionality of the FCU1 transgene integrated into the genome of TG6002. These positive initial translational data, combined with a satisfactory tolerability profile, have allowed us to continue this Phase 1 clinical trial and evaluate higher doses of this promising new drug candidate,” External link

4-traders Tuesday, September 8, 2020 7:02:00 PM EAT

Maud Brandely added : "Patients with HPV16-induced cancers still do not have access to approved treatments designed to address the viral origin of their disease. We believe these data establish the clinical proof-of-concept of combining TG4001 with an immune checkpoint inhibitor. Based on these promising findings, Transgene intends to continue the clinical development of TG4001 in a larger, controlled confirmatory study and provide a better treatment option to this patient population," External link

4-traders Wednesday, July 22, 2020 6:15:00 PM EAT

Maud Brandely added : "With BT-001, we are looking to combine Transgene's potent oncolytic virus with the local production of a high concentration of an anti-CTLA4 antibody. We believe that BT-001 will have an improved tolerability due to its ability to generate high concentrations of the antibody in the tumor and very low systemic concentrations. With this next-generation oncolytic virus, we hope to demonstrate that we can increase the antitumor activity without exposing patients to unnecessary adverse events," External link

news-yahoo Tuesday, March 3, 2020 11:32:00 AM EAT

Maud Brandely added : "With BT-001, we are looking to combine Transgene's potent oncolytic virus with the local production of a high concentration of an anti-CTLA4 antibody. We believe that BT-001 will have an improved tolerability due to its ability to generate high concentrations of the antibody in the tumor and very low systemic concentrations. With this next-generation oncolytic virus, we hope to demonstrate that we can increase the antitumor activity without exposing patients to unnecessary adverse events," External link

finanznachrichten-en Tuesday, March 3, 2020 11:29:00 AM EAT

Maud Brandely added : “With BT-001, we are looking to combine Transgene’s potent oncolytic virus with the local production of a high concentration of an anti-CTLA4 antibody. We believe that BT-001 will have an improved tolerability due to its ability to generate high concentrations of the antibody in the tumor and very low systemic concentrations. With this next-generation oncolytic virus, we hope to demonstrate that we can increase the antitumor activity without exposing patients to unnecessary adverse events,” External link

4-traders Tuesday, March 3, 2020 10:56:00 AM EAT

Maud Brandely said : “We are looking forward to reporting the first efficacy data of our active immunotherapy TG4010, with nivolumab and chemotherapy as a first-line treatment of advanced lung cancer for patients whose tumors express low or undetectable levels of PD-L1” External link

businesswire Tuesday, May 28, 2019 1:48:00 AM EAT

Maud Brandely said : "We are looking forward to reporting the first efficacy data of our active immunotherapy TG4010, with nivolumab and chemotherapy as a first-line treatment of advanced lung cancer for patients whose tumors express low or undetectable levels of PD-L1" External link

4-traders Monday, May 27, 2019 8:32:00 PM EAT

Maud Brandely said : "We are looking forward to reporting the first efficacy data of our active immunotherapy TG4010, with nivolumab and chemotherapy as a first-line treatment of advanced lung cancer for patients whose tumors express low or undetectable levels of PD-L1" External link

finanznachrichten-en Monday, May 27, 2019 7:45:00 PM EAT

Maud Brandely said : “We are looking forward to reporting the first efficacy data of our active immunotherapy TG4010, with nivolumab and chemotherapy as a first-line treatment of advanced lung cancer for patients whose tumors express low or undetectable levels of PD-L1” External link

4-traders Monday, May 27, 2019 7:40:00 PM EAT

Maud Brandely said : “We are very pleased to have been granted an IND for TG4050 by the FDA allowing us to commence the first trial with our lead myvac candidate in ovarian cancer patients who have already received first-line treatment” External link

4-traders Monday, May 13, 2019 9:27:00 AM EAT



Key Titles and Phrases Count Lang Last Seen
directeur33.33%FR07/22/201622/07/2016
chief66.67%EN07/21/201621/07/2016
Names Lang Count
Maud BrandelyEN66.67%
Maud BrandelyFR33.33%


 
Show/hide duplicate news articles.
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Monday, October 26, 2020

9:49:00 PM EAT

Languages Collapse menu...Expand menu...

Select your languages

af
am
ar
de
en
es
fr
ha
pt
rw
sw
all
Show additional languagesHide additional languages

Interface:

Legend Collapse menu...Expand menu...


Quotes... Explore Relations


EMM Visual Explorer


AfricaBrief

Maud Brandely

Last updated on 2016-07-22T11:05+0300.

About this image

sign

Quotes... Extracted quotes from

Maud Brandely said : “This is the first clinical study demonstrating that Transgene’s Vaccinia Virus from the Invir.IO platform is able to reach the tumor when administered intravenously. Importantly, through the production of 5-FU at therapeutic doses, we have also demonstrated the functionality of the FCU1 transgene integrated into the genome of TG6002. These positive initial translational data, combined with a satisfactory tolerability profile, have allowed us to continue this Phase 1 clinical trial and evaluate higher doses of this promising new drug candidate,” External link

4-traders Tuesday, September 8, 2020 7:02:00 PM EAT

Maud Brandely added : "Patients with HPV16-induced cancers still do not have access to approved treatments designed to address the viral origin of their disease. We believe these data establish the clinical proof-of-concept of combining TG4001 with an immune checkpoint inhibitor. Based on these promising findings, Transgene intends to continue the clinical development of TG4001 in a larger, controlled confirmatory study and provide a better treatment option to this patient population," External link

4-traders Wednesday, July 22, 2020 6:15:00 PM EAT

Maud Brandely added : "With BT-001, we are looking to combine Transgene's potent oncolytic virus with the local production of a high concentration of an anti-CTLA4 antibody. We believe that BT-001 will have an improved tolerability due to its ability to generate high concentrations of the antibody in the tumor and very low systemic concentrations. With this next-generation oncolytic virus, we hope to demonstrate that we can increase the antitumor activity without exposing patients to unnecessary adverse events," External link

news-yahoo Tuesday, March 3, 2020 11:32:00 AM EAT

Maud Brandely added : "With BT-001, we are looking to combine Transgene's potent oncolytic virus with the local production of a high concentration of an anti-CTLA4 antibody. We believe that BT-001 will have an improved tolerability due to its ability to generate high concentrations of the antibody in the tumor and very low systemic concentrations. With this next-generation oncolytic virus, we hope to demonstrate that we can increase the antitumor activity without exposing patients to unnecessary adverse events," External link

finanznachrichten-en Tuesday, March 3, 2020 11:29:00 AM EAT

Maud Brandely added : “With BT-001, we are looking to combine Transgene’s potent oncolytic virus with the local production of a high concentration of an anti-CTLA4 antibody. We believe that BT-001 will have an improved tolerability due to its ability to generate high concentrations of the antibody in the tumor and very low systemic concentrations. With this next-generation oncolytic virus, we hope to demonstrate that we can increase the antitumor activity without exposing patients to unnecessary adverse events,” External link

4-traders Tuesday, March 3, 2020 10:56:00 AM EAT

Maud Brandely said : “We are looking forward to reporting the first efficacy data of our active immunotherapy TG4010, with nivolumab and chemotherapy as a first-line treatment of advanced lung cancer for patients whose tumors express low or undetectable levels of PD-L1” External link

businesswire Tuesday, May 28, 2019 1:48:00 AM EAT

Maud Brandely said : "We are looking forward to reporting the first efficacy data of our active immunotherapy TG4010, with nivolumab and chemotherapy as a first-line treatment of advanced lung cancer for patients whose tumors express low or undetectable levels of PD-L1" External link

4-traders Monday, May 27, 2019 8:32:00 PM EAT

Maud Brandely said : "We are looking forward to reporting the first efficacy data of our active immunotherapy TG4010, with nivolumab and chemotherapy as a first-line treatment of advanced lung cancer for patients whose tumors express low or undetectable levels of PD-L1" External link

finanznachrichten-en Monday, May 27, 2019 7:45:00 PM EAT

Maud Brandely said : “We are looking forward to reporting the first efficacy data of our active immunotherapy TG4010, with nivolumab and chemotherapy as a first-line treatment of advanced lung cancer for patients whose tumors express low or undetectable levels of PD-L1” External link

4-traders Monday, May 27, 2019 7:40:00 PM EAT

Maud Brandely said : “We are very pleased to have been granted an IND for TG4050 by the FDA allowing us to commence the first trial with our lead myvac candidate in ovarian cancer patients who have already received first-line treatment” External link

4-traders Monday, May 13, 2019 9:27:00 AM EAT



Key Titles and Phrases Count Lang Last Seen
directeur33.33%FR07/22/201622/07/2016
chief66.67%EN07/21/201621/07/2016
Names Lang Count
Maud BrandelyEN66.67%
Maud BrandelyFR33.33%


<<10<12345678910>>>10
<<10<12345678910>>>10

Tools

Load latest edition

Monday, October 26, 2020

9:49:00 PM EAT


Quotes... Explore Relations


EMM Visual Explorer